Clinical Trial Update: Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of BI 2536 for advanced or metastatic non-small cell lung cancer; results have been posted after completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BI-2536

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2022-05-06